# Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

> **NCT00574496** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** cyclosporine
- **DRUG:** fludarabine phosphate
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** ifosfamide
- **DRUG:** mechlorethamine hydrochloride
- **DRUG:** melphalan
- **DRUG:** methotrexate
- **DRUG:** mycophenolate mofetil
- **DRUG:** prednisone
- **DRUG:** procarbazine hydrochloride
- **DRUG:** vincristine sulfate
- **DRUG:** vinorelbine tartrate
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** nonmyeloablative allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **PROCEDURE:** umbilical cord blood transplantation
- **RADIATION:** total-body irradiation

## Key facts

- **NCT ID:** NCT00574496
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-13
- **Primary completion:** 2022-08-02
- **Final completion:** 2022-08-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574496, "Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00574496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*